Bekaii-Saab, T. S., Van Cutsem, E., Tabernero, J., Siena, S., Yoshino, T., Nakamura, Y., … Strickler, J. H. (2023). MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. TPS261–TPS261).

Bekaii-Saab, Tanios S., Eric Van Cutsem, Josep Tabernero, Salvatore Siena, Takayuki Yoshino, Yoshiaki Nakamura, Kanwal Pratap Singh Raghav, et al. “MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.” In JOURNAL OF CLINICAL ONCOLOGY, 41:TPS261–TPS261, 2023.

Bekaii-Saab TS, Van Cutsem E, Tabernero J, Siena S, Yoshino T, Nakamura Y, et al. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress. In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS261–TPS261.

Bekaii-Saab, Tanios S., et al. “MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. TPS261–TPS261.

Bekaii-Saab TS, Van Cutsem E, Tabernero J, Siena S, Yoshino T, Nakamura Y, Raghav KPS, Cercek A, Heinemann V, Adelberg DE, Ward JE, Yang S, Andre T, Strickler JH. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress. JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS261–TPS261.